DE-THE-LYCRA-COMPANY
The LYCRA Company , a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, will join a panel discussion at the inaugural United Nations Conscious Fashion and Lifestyle Network Annual Meeting taking place at the United Nations Headquarters in New York City on June 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005251/en/
With its recent commercialization of COOLMAX® and THERMOLITE® fibers made from 100% textile waste, The LYCRA Company is uniquely positioned to participate in the discussion titled Responsible Consumption and Production: Designing for Our Times . Jean Hegedus, sustainability director, The LYCRA Company, will share her perspective on how the company is scaling recycling solutions to help address the challenge of textile waste.
The meeting will welcome United Nations Conscious Fashion and Lifestyle Network advisory committee members and registered partnerships by industry stakeholders, media, Governments and United Nations system entities to highlight actions, solutions, and progress from the fashion and lifestyle sectors to advance sector engagement in the implementation of the Sustainable Development Goals adopted by the United Nations Member States in 2015. Discussions will focus on confronting the climate crisis, achieving gender equality throughout the value chain, and ensuring a resilient post-pandemic recovery.
“The LYCRA Company recognizes that the journey towards a more sustainable future is a collective effort across the industry,” said Kerry Bannigan, executive director, Fashion Impact Fund. “We are thrilled to have them join our first annual meeting to discuss solutions that will accelerate the fashion and lifestyle sector’s implementation of the Sustainable Development Goals.”
As the apparel industry looks to rapidly develop solutions for a circular economy, The LYCRA Company is focused on a variety of fiber and fabric innovations that reduce or divert waste, keeping materials in use and out of landfills. The company’s EcoMade family of recycled offerings includes LYCRA® , COOLMAX® and THERMOLITE® fibers made from both pre- and post-consumer waste. The LYCRA Company invites the industry to Keep in the Loop with LYCRA to learn about its latest sustainable innovations and circularity advancements, while also promoting collaboration.
The United Nations Conscious Fashion and Lifestyle Network’s inaugural annual meeting is co-convened by the United Nations Office for Partnerships and the Fashion Impact Fund.
Spokesperson Biography:
Jean Hegedus is the sustainability director for The LYCRA Company. Ms. Hegedus has over 35 years of experience in the textile industry, working first with The DuPont Company, and then INVISTA, before moving to The LYCRA Company in 2019. Over the course of her career, she has held a variety of positions in public affairs, marketing, licensing and branding. She began working in the denim segment in 2007, bringing several important innovations to market, including LYCRA® XFIT, LYCRA® dualFX® , LYCRA® BEAUTY, and LYCRA® EcoMade technologies. It was also her work within the denim segment that heightened her awareness of the need for more sustainable solutions, and in July of 2019, she was appointed sustainability director for The LYCRA Company. Ms. Hegedus has a master’s degree in communications from the University of Delaware.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company.
About the United Nations Conscious Fashion and Lifestyle Network
The Conscious Fashion and Lifestyle Network is a United Nations (UN) hosted online platform for industry stakeholders, media, Governments, and UN system entities. The network showcases and enables collaborations that accelerate the implementation of the Sustainable Development Goals. The United Nations Conscious Fashion and Lifestyle Network is a joint initiative of the United Nations Office for Partnerships, the Division for Sustainable Development Goals - United Nations Department of Economic and Social Affairs, and the Fashion Impact Fund. The leading entities of the network convene periodic events aligned with key meetings on the UN calendar and publish reports on the network’s achievements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005251/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom